Kornimate/medical-research-clean huggingface dataset:
comparison of therapeutic effect of different brace fixed time after novel achilles tendon rupture surgery

Conditions: Achilles Tendon Rupture

Summary: this study is a prospective randomized controlled clinical study. after the novel achilles tendon rupture repaired , patients were randomly divided into 4 groups according to immobilisation duration of 0, 2, 4, and 6 weeks, respectively. all patients underwent the same suture technique with a similar rehabilitation protocol and were examined clinically at 2, 4, 6, 8, 10, 12, 14, 16, 24, and 48 weeks to study the difference in efficacy among the groups.

this prospective randomized controlled clinical study is designed to compare the treatment outcomes of different immobilisation duration by dividing the patients into four groups according to immobilisation duration of 0, 2, 4, and 6 weeks after a similar suture technique. the primary outcome was the time of return to light sports activity (lsa). secondary outcomes included range of motion (rom) and single-legged heel rise height (shrh). data on operation time, complications, visual analogue pain scale (vas), american orthopaedic foot and ankle society (aofas) hindfoot score, and achilles tendon total rupture score (atrs) were also collected. demographic baseline data were analysed using one-way analysis of variance; outcome parameters were analysed using kruskal-wallis h test, and complications were analysed using fisher's exact test. statistical significance was considered at p ≤ 0.05. the inclusion criteria were patients aged 18 to 60 years with an acute closed single-legged complete atr who underwent open surgery with our suture technique. the excluded criteria were patients with prior atr and those without rehabilitation or follow-up outcomes. other situations that affected patients' lower limb functions or tendon healing (e.g. autoimmune disease, diabetes mellitus, systemic corticosteroid treatment) were also excluded.

Eligibility criteria:
inclusion criteria: patients aged 18 to 60 years with an acute closed single-legged complete atr who underwent open surgery with our suture technique. exclusion criteria: * patients with prior achilles tendon rupture or other situations that affected their lower limb functions or tendon healing (e.g., autoimmune disease, diabetes mellitus, systemic corticosteroid treatment). * an inability to complete our suture technique (e.g., the distance from the rupture site to the achilles tendon insertion was less than 3.5 cm) . * those without rehabilitation or follow-up outcomes.

Keywords: duration of immobilisation
sub-dissociative intranasal ketamine for pediatric sickle cell pain crises

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises in resource-limited settings.

this is a randomized, placebo-controlled, drug trial using sub-dissociative intranasal ketamine as an adjunct to standard pharmacotherapy for the management of pediatric sickle cell disease vasoocclusive pain crises in resource-poor settings. pediatric patients will be enrolled at a teaching and referral hospital in west africa. patients will be randomly assigned to the treatment arm - standard therapy plus sub-dissociative intranasal ketamine (1 mg/kg) given at time zero) or the control arm - standard therapy plus intranasal normal saline (volume-matched to treatment arm), and patients will evaluated at standard intervals to assess for pain scores and vital signs (0 minutes, 30 minutes, 60 minutes, and 120 minutes). pain will be assessed using the faces pain scale - revised (fps-r). patients will also be observed for any potential side effects or adverse events. all patients will be contacted 2-3 weeks post intranasal medication administration for over-the-phone follow-up using a portion of the pedsql-scd questionnaire, to assess for basic quality of life related to pain management and treatment.

Eligibility criteria:
inclusion criteria: * sickle cell disease (scd) * vasoocclusive pain crisis * requiring analgesia exclusion criteria: * anatomic variations of nose precluding intranasal medication administration * ketamine allergy * non-verbal * obtunded * pregnant * other acute scd complications: * acute chest syndrome * sepsis * stroke * splenic sequestration * pulmonary embolism * acute osteomyelitis

Keywords: ketamine intranasal pain crisis vasoocclusive pain sickle cell disease
effect of remimazolam vs sevoflurane anesthesia on incidence of emergence agitation and complications in children undergoing ophthalmic surgery

Conditions: Emergence Agitation; Remimazolam; Sevoflurane; Pediatric Ophthalmic Surgery; Anesthesia, General

Summary: as a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. this study aims to investigate whether remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (rct).


Eligibility criteria:
inclusion criteria: 1. asa ⅰ-ⅱ 2. aged 3-8 years, weight \> 10 kg, sex was not limited； 3. children were scheduled for selective ophthalmic surgery under general anesthesia, exclusion criteria: 1. respiratory infection was present within 4 weeks before surgery. 2. potential or presence of difficult airways, airway obstruction, sleep apnea, and other contraindications to general anesthesia. 3. the blood routine or blood biochemical indexes were obviously abnormal. 4. allergy or hypersensitive reaction to test drug, including remimazolam, sevoflurane, and remifentanil. 5. any child who has taken benzodiazepines in the last 3 months. 6. unable to cooperate to complete the test, and the guardian refused to attend. 7. other reasons that researchers hold it is not appropriate to participate in this trial.

Keywords: anesthesia, general pediatric ophthalmic surgery emergence agitation remimazolam sevoflurane
comparison of hepatic intraarterial versus systemic intravenous 68ga-psma pet/ct for detection of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this phase 0/1 study evaluates intraarterial administration of gallium ga 68 gozetotide (68ga-psma) for the detection of prostate-specific membrane antigen (psma) positive liver cancer by positron emission tomography (pet)/computed tomography (ct). 68ga-psma is an imaging agent used with pet/ct scans to locate psma positive lesions. this study evaluates intraarterial administration of this agent, compared to intravenous administration.

primary objective: i. to determine the tumor radiotracer uptake (first pass effect or regional advantage) of direct hepatic intraarterial (i.a.) versus systemic intravenous (i.v.) 68ga-psma in patients with psma+ hepatocellular carcinoma (hcc) by pet/ct. outline: patients undergoing clinically indicated hepatic artery embolization will receive 68ga-psma intraarterially (ia) over 5 minutes. after 60-90 minutes, patients undergo pet/ct scan over 1 hour.

Eligibility criteria:
inclusion criteria: * patients with either an imaging diagnosis of hcc by ct or magnetic resonance imaging (mri) (liver imaging and reporting data system 5 \[li-rads 5\]) confirmed by a board-certified abdominal radiologist, or with biopsy-proven hcc * already enrolled in ongoing transform the practice or department of defense 68ga-psma studies * psma avid hcc detected by 68ga-psma pet/ct after intravenous administration of 68ga-psma confirmed by a board certified nuclear radiologist * undergoing planned hepatic artery embolization (hae) per standard clinical care * male or female with age greater than 18 years, with the capacity and willingness to provide a written informed consent exclusion criteria: * subjects requiring emergent surgery for a ruptured/bleeding hcc * pregnant and/or breast-feeding subjects. a negative pregnancy test within 48 hours of the pet scan * subjects with higher than the weight/size limitations of pet/ct scanner
gait and muscle power training for children with developmental coordination disorder

Conditions: Developmental Coordination Disorder

Summary: objectives: to compare the effectiveness of ras-mpt, ras alone, mpt alone, and usual care (as a control) for improving the overall gait performance of and reducing falls in children with developmental coordination disorder (dcd) and to explore the relationship between gait performance and falls in this population. design: a randomized controlled trial. sample: 76 children with dcd. interventions: ras-mpt, ras alone, mpt alone, or usual care (12 weeks). major outcomes: outcomes will be evaluated at baseline, post-intervention, and a 6-month follow-up. comprehensive gait analysis will produce spatiotemporal gait parameters (e.g., velocity and stride length), kinematic gait parameters (e.g., knee joint motions), and leg muscle emg outcomes; an isokinetic test will quantify leg muscle strength and force production time; and fall histories will be obtained via interviews. anticipated results and significance: the ras-mpt group is predicted to display the best gait performance, which is associated with reduced fall incidents. this novel training regime can be readily adopted in school, clinical, or home settings to improve locomotor ability in children with dcd, an outcome with positive socioeconomic implications.


Eligibility criteria:
inclusion criteria: * 6 to 9 years old * classified as dcd according to the diagnostic and statistical manual of mental disorders v * \< 5th percentile on the movement assessment battery for children-2 (mabc-2) * a total score of \< 46 (for children aged 6 to 7 years 11 months) or \< 55 (for children aged 8 to 9 years) on the dcd questionnaire 2007 (chinese version) * attending a mainstream school (i.e., intelligence level within the normal range). exclusion criteria: * any congenital, cognitive, psychiatric (e.g., comorbid attention deficit hyperactivity disorder or autism spectrum disorder), neurological, sensory, hearing, visual, vestibular, musculoskeletal, or cardiopulmonary disorder that may affect test performance * obesity (body mass index \[bmi\] \>95th percentile) * receiving active treatment such as physiotherapy * those unable to follow instructions.
vasopressin deficiency in hemorrhagic shock

Conditions: Body Response to Trauma

Summary: in this study we hope to delineate the typical vasoactive mediator response of trauma patients to shock. we plan to assess serum levels of vasopressin and also catecholamines, angiotensin, and cortisol during resuscitation of trauma patients to delineate high risk populations for vasopressin deficiency.

this is a prospective observational study. the only research-driven procedure will be the removal of blood samples at designated time points(total blood removed 48 cc per patient). hemodynamic, fluid infusion and agitation/pain data (ramsey score) will prospectively be collected for research purposes. we will collect data from a convenience sample of patients (when research staff is available) over a one year period.

Eligibility criteria:
inclusion criteria: * patient is a male or female patient presumed to be at least 18 years of age; * patient has a reported or actual systolic blood pressure \< 90 mmhg within 1 hour of arrival to the emergency room; * patient has clinical evidence of acute traumatic injury; exclusion criteria: * patient is asystolic or requires cpr prior to arrival; * patient was transferred from an outside facility * patient known to be pregnant * patient known to be prisoner
cerebral nirs monitoring during anesthesia in neonates and infants

Conditions: Cerebral Oxygenation

Summary: the brain is a very vulnerable organ, especially in premature babies, newborns and infants. however, during anesthesia, the oxygenation of the brain can only be monitored indirectly and insufficiently. near-infrared spectroscopy (nirs) is an established monitoring method in other areas (e.g., neonatology, cardiac anesthesia), which provides non-invasive information about the regional oxygen supply of the brain. the integration of this monitoring device into the anaesthesiological care for neonates and infants could reduce the risk of cerebral hypoxia. the planned study investigates whether the use of nirs in anesthetized children up to 6 months can prevent or influence the occurrence of cerebral hypoxia.


Eligibility criteria:
inclusion criteria: * expected duration of anesthesia \>45 minutes * intervention/surgery in the operating room exclusion criteria: * impossibility to place cerebral nirs sensor * known cerebral pathology * missing parental consent * congenial cardiac condition with right to left shunt * cardiac surgery
5-azacytidine prior to allogeneic stem cell transplant in high risk myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome

Summary: the purpose of this study is to examine the feasibility and efficacy of using the demethylating agent 5-azacytidine prior to allogeneic stem cell transplantation in patients with high risk myelodysplastic syndrome (mds).

the study drug, 5-azacytidine, is given daily intravenously for 7 days. after every 2 cycles study participants will have a bone marrow test to evaluate the effect of the 5-azacytidine on the myelodysplastic syndrome (mds). participants continue to get cycles of 5-azacytidine until 2 bone marrow tests show the mds has stopped responding to the treatment. at that time they will undergo a transplant if a donor is available.

Eligibility criteria:
inclusion criteria: * patients fulfilling the following criteria will be eligible for study entry: 1. diagnosis of mds according to who criteria 2. intermediate-2 or high risk by ipss score 3. clinically able to receive 5-azacytidine 4. serum bilirubin levels \</=1.5 times the upper limit of the normal range for the laboratory (uln). higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis 5. serum glutamic-oxaloacetic transaminase (sgot) or serum glutamic-pyruvic transaminase (sgpt) levels \</=2 x uln 6. serum creatinine levels \</=1.5 x uln 7. negative serum pregnancy test prior to 5-azacytidine treatment for women of childbearing potential 8. women and men of childbearing potential agree to use contraception while receiving treatment with 5-azacytidine 9. potentially eligible for allogeneic transplantation 10. no prior allogeneic transplant 11. age 18 to 70, inclusive. exclusion criteria: 1. known or suspected hypersensitivity to 5-azacytidine or mannitol 2. patients previously treated with 5-azacytidine or deoxyazacytidine 3. pregnant or breast feeding 4. patients with advanced malignant hepatic tumors

Keywords: myelodysplastic syndrome 5-azacytidine allogeneic stem cell transplantation
pap smear collection with the papette brush

Conditions: Cervical Cancer Screening

Summary: this research study is comparing pap smear collection techniques using the papette brush to traditional spatula and cytology brush for cervical cancer screening

at the investigators institution the investigators have been using both the traditional spatula and cytology and the papette brush for pap smear collection. the investigators will be comparing adequacy of sample rates, provider perceived pain and bleeding and overall satisfaction with each collection technique.

Eligibility criteria:
inclusion criteria: * adult women, aged 21-64 years old. * have given consent for medical records to be accessed. * who will have a pap smear exam in cim from july 2021 through june 2022. exclusion criteria: * women, age \ 64. * has vaginal spotting present during cervical sampling. * did not give consent to have medical records accessed.

Keywords: pap smear collection
radiographic evaluation of a star-shaped incision technique

Conditions: Clinical and Radiographic Effect; Thick-gingiva; Thin-gingiva; Implant

Summary: to evaluate a star-shaped incision technique to thick-gingiva and thingingiva patients treated with implant-supported fixed prosthesis. the star-shaped incision would be an effective and simple method to reconstruct gingival papillae and avoid the gingival recession in thick-gingiva patients treated with implant-supported fixed prosthesis, and it is worthy of clinical extend.

objective: to evaluate a star-shaped incision technique to thick-gingiva and thin-gingiva patients treated with implant-supported fixed prosthesis. methods and materials: 24 patients received cross-shaped incision were assigned into thick-gingiva group (16 cases) and thin-gingiva group (8 cases). follow-up examination was carried out 3 and 12 months after final restoration. clinical and radiographic evaluation including gingival papilla height, modified plaque index, modified sulcus bleeding index, periodontal depth, and crestal marginal bone level were utilized.

Eligibility criteria:
inclusion criteria 1. good general health, no chronic systemic diseases. 2. all subjects included in this study needed to have one missing premolar or molar teeth with adjacent natural teeth. 3. all subjects included in this study had been treated with one bone-level implant insertion in the premolar or molar region. the patients had insufficient gingival papilla height (referred to contralateral natural tooth which also had insufficient gingival papilla height) and at least 2 mm of keratinized tissue width around the implant. exclusion criteria 1. active periodontal infections. 2. heavy smoking (\> 10 cigarettes per day).
histological analysis of allomend® acellular dermal matrix used in breast implant surgeries

Conditions: Breast Implant; Complications, Infection or Inflammation

Summary: this is a prospective, histologic analysis of biopsied tissue obtained from participants who have undergone a pre-pectoral breast reconstruction or augmentation surgery with expander placement and allomend® acellular dermal matrix. allomend® acellular dermal matrix graft incorporation with surrounding native soft tissue using histological assays characterizing host cell infiltration, neovascularization, inflammation, and host replacement of adm collagen will be studied.

the purpose of this study is to evaluate the incorporation of allomend® acellular dermal matrix with native surrounding tissue by obtaining up to three, 1 cm diameter biopsies per breast. the samples will then be transported to allosource research and development labs for slide preparation and histologic analysis. this study will be performed at one (1) clinical center in the united states.

Eligibility criteria:
inclusion criteria: * ≥18 years of age; * allomend® acellular dermal matrix used during the initial prepectoral placement of tissue expanders for breast reconstruction; * is scheduled or will be scheduled for a procedure to exchange the tissue expander for permanent breast implant; * can understand the requirements of the study, has provided written, informed consent, and to comply with the study protocol. exclusion criteria: * mentally compromised (e.g., being currently treated for a psychiatric disorder, senile dementia, alzheimer's disease) in a manner that would compromise his or her ability to consent to participate in the clinical study; * subjects who, in the opinion of the investigator, would not be able or willing to comply with the protocol.
comparison of met vs mobilization in management of post-partum backache in females (nvd) and cesarean section delivery

Conditions: Cesarean Section Complications

Summary: effectiveness comparison of effects of muscle energy technique (met) vs mobilization in management of post-partum backache in females with normal vaginal delivery (nvd) and cesarean section delivery


Eligibility criteria:
inclusion criteria: * subjects with age group 20 to 40 year. * low back pain and disability after normal vaginal delivery or c-section delivery will be included. exclusion criteria: * subjects who had neurological deficit. * spinal tumors, scoliosis * underwent spinal surgery * prolapsed intervertebral disc with or without radiculopathy will be excluded.
non-surgical interventions for infertility in endometriosis

Conditions: Endometriosis; Infertility, Female

Summary: a parallel design randomized clinical trial was carried out on 18 women with clinically diagnosed endometriosis who wish pregnancy in the department of reproductive endocrinology and infertility, bangabandhu sheikh mujib medical university, (bsmmu), shahbag, dhaka. those who voluntarily provide consent to participate in this study will be randomly allocated to one of the two treatment arms. allocation concealment will be done by sequentially numbered sealed envelopes. the arms and interventions are cabergoline (0.5 mg twice weekly for 6 months, plus timed intercourse) and dydrogesteron (20 mg daily from day 5 to day 25 of menstrual cycle for 6 months, plus timed intercourse).the women will be assessed by telephone interview at monthly intervals, tvs and serum ca 125 at 3 months and 6 months.

infertile women with endometriosis will be recruited from those attending dept of reproductive endocrinology and infertility after clinical diagnosis on the basis of sonographic findings of chocolate cyst with or without dysmenorrhea. after evaluating for eligibility criteria and taking informed consent she will be randomized to either cabergoline group or to dydrogesterone group. women assigned to cabergoline group will receive 0.5 mg cabergoline twice weekly (fridays and tuesdays), after meal at night for 6 months. the dydrogesterone group will receive 10 mg of dydrogesterone twice daily from day 5 to day 25 of menstrual cycle for six months. she will be followed up every month to check for compliance or any side effects. the couple will have intercourse timed with lh kit or intercourse on alternate days from day 10 to day 15 of the cycle if the lh kit is not available. she will visit 3 months and 6 months after the beginning of treatment. at each follow up visit, she will be assessed for pregnancy, visual analog scale for pain and transvaginal sonogram to measure the chocolate cyst. estimation of serum ca125 and any side effects will be noted.

Eligibility criteria:
inclusion criteria: 1. women of reproductive age 18-35 yrs 2. women who are infertile or wish pregnancy 3. sonographic diagnosis of chocolate cyst with or without dysmenorrhea 4. women staying with her husband exclusion criteria: 1. recurrent endometrioma after previous surgery 2. bmi at or more than 30 kg/m2 3. significant abnormalities in renal and liver function. 4. known male factor 5. use of investigational drugs or hormones, concomitant or in last 30 days.

Keywords: endometriosis
effects of an intervention program based on pain education in patients with chronic pelvic pain

Conditions: Pelvic Pain

Summary: the purpose of this study is to obtain imaging biomarkers based on changes in activity patterns and changes in brain connectivity obtained with the analysis of functional magnetic resonance imaging (fmri) and tractography that are related to chronic pelvic pain


Eligibility criteria:
inclusion criteria: * age between 18 and 55 years * chronic pelvic pain diagnosis * pain duration \> 6 months * average pain intensity ≥ 6 during the previous week exclusion criteria: * suspected or knowledge of actual organic pathology that requires medical or surgical treatment * psychiatric illness: major depression, bipolar syndrome... * patients with significant cognitive deficits * have pacemaker, metal prostheses or hearing aids incompatible with mri * severe traumatic brain injury * previous cranial surgeries * history of alcoholism * do not sign informed consent